You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股消息》加科思药业(01167.HK)今日起招股 入场费4,242.32元
阿思达克 12-09 09:43
临床阶段制药公司加科思药业(01167.HK)公布招股详情,计划发售9,647.61万股股份,当中10%在港公开发售,招股价介乎每股12至14元,每手300股,入场费为4,242.32元。由今日(9日)至下周一(14日)公开招股,预计於12月21日上市。高盛及中金为联席保荐人。

公司为上市引入6名基石投资者,包括LAV Funds、Matthews Funds、哈德逊湾资本、Octagon Investments等,合共认购6,000万美元股份。

以招股价中位数13元计,公司预计集资所得款项净额约为11.71亿元,当中88%将主要用於产品的临床开发及商业化;8%将用於建造符合GMP标准的内部生产设施;余下4%将作为一般企业及营运资金用途。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account